MLAB Mesa Laboratories Inc.

Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure

Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure

LAKEWOOD, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”) is a global leader in the design and manufacture of life science tools and critical quality control solutions. Mesa has monitored the situation at Silicon Valley Bank (“SVB”), whereby on March 10, 2023, the California Department of Financial Protection and Innovation closed SVB and placed it under control of the United States Federal Deposit Insurance Corporation (“FDIC”) as receiver.  According to the FDIC,  depositors will have access to all of their money starting Monday, March 13, 2023.

Mesa has taken proactive steps to mitigate risk to the Company, which continues to believe that its existing cash and cash equivalents balance and cash flow from operations will be sufficient to meet its working capital, capital expenditures, and material cash requirements from known contractual obligations for the foreseeable future.

Mesa’s deposit accounts held at SVB in excess of the $250,000 FDIC-insured limits are less than $500,000. Mesa believes this is immaterial when compared to the Company’s total balance of cash and cash equivalents which were $26.1 million as of December 31, 2022 and are held on deposit at multiple large financial institutions across the world. Other than the deposit accounts noted, Mesa has no material positions or relationships with SVB.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries.  Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Biopharmaceutical Development, Clinical Genomics, and Calibration Solutions) to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.



Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc.,  

For more information about the Company, please visit its website at 
EN
13/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mesa Laboratories Inc.

 PRESS RELEASE

Mesa Labs Announces Third Quarter Results

Mesa Labs Announces Third Quarter Results LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q26”) ended December 31, 2025 (amounts in thousands). 3Q26 Financial Summary – (comparisons are versus the same year ago period Revenues increased 3.6%Non-GAAP organic and core organic revenues1 growth was 3.6% and 1.2%, respectivelyNon-GAAP organic revenues growth exclu...

 PRESS RELEASE

MESA LABS DECLARES QUARTERLY DIVIDEND

MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharm...

 PRESS RELEASE

Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Confere...

Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time. A live webcast of the presentation will be accessi...

 PRESS RELEASE

Mesa Laboratories, Inc. to Announce Third Quarter Results on February ...

Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026 LAKEWOOD, Colo., Dec. 03, 2025 (GLOBE NEWSWIRE) --  - Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern Time (ET) on Tuesday, February 3, 2026. About Mesa LaboratoriesMesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and se...

 PRESS RELEASE

Mesa Laboratories, Inc. to Participate in Upcoming Investor Conference...

Mesa Laboratories, Inc. to Participate in Upcoming Investor Conferences LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that Gary Owens, President and CEO, and John Sakys, CFO will be attending the following upcoming conferences: Raymond James Napa Valley Small Cap SymposiumFormat: 1x1 Meetings Date: Monday, November 17, 2025Jefferies London Healthcare Conference Format: Fireside chatDate: Thursday, November 20, 2025Time: 12:00 p.m. GMTWebcast: 8th Annual Evercore Healthcare ConferenceFormat: Fireside chat Date: Wednesday, Decemb...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch